At a glance
ClinicalIndex Comparison RecordN/ACompleted· 52 enrolled
Drug / intervention
axitinib: observational studydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Retrospective Observational Study Of Subjects With Cytokine-Refractory Metastatic Renal Cancer Treated With Axitinib (AG-013736) To Estimate 5-Yr Survival
In Brief
An observational study evaluating axitinib: observational study for Carcinoma, Renal Cell. Completed, enrolled 52 participants across 8 sites in 3 countries.
Detailed Summary
The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 \[NCT00076011\] study to estimate the 5-year survival rate in subjects with metastatic renal cancer cell treated with axitinib.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesFrance, Germany, United States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2010
Enrollment StartApr 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedJan 26, 2010
Enrollment StartApr 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.4 years ago
Interventions
axitinib: observational studydrug
Non-interventional observational study